European Journal of Molecular & Clinical Medicine

Abstract

Diagnostic approach and treatment of recurrent ovarian cancer has many
unresolved issues, the relevance of which is associated with late diagnosis and ultimately
low treatment effectiveness and high mortality rates. The clinical manifestation of
recurrent ovarian cancer is variable even within a morphologically similar group of
patients due to the high degree of heterogeneity of the tumor. Questions remain about how
wide the range of molecular genetic markers is and what is the correlation between their
level and the effectiveness of treatment for ovarian cancer recurrence. One of the most
promising ways to obtain information about the nature of the recurrence of the tumor
process in ovarian cancer (OC) can be the study of ascitic fluid (AF).